PCK2 and hepatocellular carcinoma: Supplementation of rat hepatoma cells (H4IIE) with (1–25 μg/mL) CE was demonstrated to inhibit hepatic glucose production by downregulating the expression of PEPCK and G6pase (Figure 2), concomitantly decreasing blood glucose levels [126].